Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Novartis
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00673608CT.gov Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload | — | Completed | — | — | — |
NCT00171301CT.gov Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) | — | Completed | — | — | — |
NCT00303329CT.gov Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients | — | Completed | — | — | — |
NCT00390858CT.gov A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deferasirox (this asset) | Novartis | Approved | BBB · 72 |
| Epoetin Alfa | Mayo Clinic | P4 | BBB |
| Erythropoietin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Epoetin Beta | Institut du Cancer de Montpellier - Val d'Aurelle | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | BBB |
| Darbepoetin Alfa | Amgen | P3 | BBB |
| Cyclophosphamide | OHSU Knight Cancer Institute | P4 | BBB |
| Ferric Cation | National Cancer Center, Korea | P4 | BBB |
| Methoxy Polyethylene Glycol-Epoetin Beta | Taipei Veterans General Hospital, Taiwan | P4 | BBB |
+42 more in the Anemia cohort
Other indications for Deferasirox
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Iron Poisoning | — | P4 | A · 82 |
| Hemosiderosis | — | P4 | A · 81 |
| Beta-Thalassemia Major | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Deferasirox in Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/deferasirox-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →